Biogen-Samsung's Enbrel biosimilar cleared for EU marketing

Biogen-Samsung's Enbrel biosimilar cleared for EU marketing

The European Commission approved Samsung Bioepis' Benepali version of Enbrel (etanercept) for the treatment of adults with moderate to severe rheumatoid arthritis, psoriatic arthritis, non-radiographic axial spondyloarthritis and plaque psoriasis. The

(Visited 6 times, 1 visits today)
5
Like
Save

Comments

Comments are disabled for this post.